AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17425550 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) via vacuum-assisted closure (VAC) device
Number of subjects: 162
Study 17425550 — intervention group
Group type: COMPARATOR
Intervention: Standard wound therapy (SWT)
Number of subjects: 162
Study 16330293 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐mg nicotine lozenge
Number of subjects: 901
Study 16330293 — intervention group
Group type: COMPARATOR
Intervention: 4‐mg nicotine gum
Number of subjects: 901
Study 11989996 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 20
Study 11989996 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 20
Study 9459471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine 0.4 mg/kg
Number of subjects: 24
Study 9459471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine 0.2 mg/kg
Number of subjects: 24
Study 9459471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7888260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous naloxone
Number of subjects: 18
Study 7888260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7888260 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta endorphin concentrations
Number of subjects: 18
Study 2145791 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol (10 micrograms/inhalation)
Number of subjects: 53
Study 2145791 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (90 micrograms/inhalation)
Number of subjects: 53
Study 2145791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 645799 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal delivery
Number of subjects: 127
Study 645799 — intervention group
Group type: COMPARATOR
Intervention: Elective cesarean section
Number of subjects: 127
Study 30922873 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid 5 to 10 mg or 10 mg once daily for 12 months, followed by variable adjusted doses during the open-label extension.
Number of subjects: 193
Study 30922873 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during the double-blind phase).
Number of subjects: 193
Study 28103640 — intervention group
Group type: EXPERIMENTAL
Intervention: DAC (daunorubicin plus cytarabine plus cladribine)
Number of subjects: 171
Study 28103640 — intervention group
Group type: COMPARATOR
Intervention: DA (daunorubicin plus cytarabine)
Number of subjects: 171
Study 25260557 — intervention group
Group type: EXPERIMENTAL
Intervention: MIND at Home intervention
Number of subjects: 289
Study 25260557 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 289
Study 24098499 — intervention group
Group type: EXPERIMENTAL
Intervention: PDF copy of the standard paper participant information sheet (PDF‐PIS)
Number of subjects: 1160
Study 24098499 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Interactive Information Sheet (IIS)
Number of subjects: 1160
Study 22256223 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 Hz 60 pulses rTMS over right SPL
Number of subjects: 0
Study 22256223 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 Hz 60 pulses rTMS over right SPL
Number of subjects: 0
Study 22256223 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz 60 pulses rTMS over right SPL
Number of subjects: 0
Study 22256223 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz 240 pulses rTMS over right SPL
Number of subjects: 0
Study 22256223 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 Hz 120 pulses rTMS over right SPL
Number of subjects: 0
Study 22256223 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 Hz 120 pulses rTMS over right SPL
Number of subjects: 0
Study 22256223 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz 120 pulses rTMS over right SPL
Number of subjects: 0
Study 22256223 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS over motor area
Number of subjects: 0
Study 19402182 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril LPH 25 mg
Number of subjects: 0
Study 19402182 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril LPH 50 mg
Number of subjects: 0
Study 19402182 — intervention group
Group type: COMPARATOR
Intervention: Capoten 50 mg
Number of subjects: 0
Study 18063208 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg IV
Number of subjects: 137
Study 18063208 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 137
Study 18063208 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide and Placebo (both groups)
Number of subjects: 137
Study 15213582 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate plus psychosocial treatment (academic remediation, organizational skills training, psychotherapy, parent training, counseling, social skills training)
Number of subjects: 103
Study 15213582 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate plus attention control treatment
Number of subjects: 103
Study 15213582 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate alone
Number of subjects: 103
Study 11572495 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary infiltration
Number of subjects: 60
Study 11572495 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular block
Number of subjects: 60
Study 9691878 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine, 8 ml/h for 24 hours
Number of subjects: 52
Study 9691878 — intervention group
Group type: COMPARATOR
Intervention: 0.2% bupivacaine, 8 ml/h for 24 hours
Number of subjects: 52
Study 9691878 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ropivacaine vs bupivacaine
Number of subjects: 52
Study 8964876 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg E2 valerate
Number of subjects: 37
Study 8964876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic increase in serum E2 concentrations in women
Number of subjects: 37
Study 8964876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 2100284 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (0.2 mg/kg)
Number of subjects: 9
Study 2100284 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (3 units)
Number of subjects: 9
Study 2100284 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin and naloxone combined
Number of subjects: 9
Study 7307425 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg propranolol intravenously (group 1)
Number of subjects: 14
Study 7307425 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group II)
Number of subjects: 14
Study 31624837 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg once daily for 16 weeks
Number of subjects: 131
Study 31624837 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 16 weeks
Number of subjects: 131
Study 31624837 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg once daily
Number of subjects: 131
Study 31624837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 31411762 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX infusion 0.5 μg/kg after delivery and PCIA with DEX plus sufentanil
Number of subjects: 600
Study 31411762 — intervention group
Group type: COMPARATOR
Intervention: Control group (infusion with 0.9% normal saline after delivery and PCIA with sufentanil)
Number of subjects: 600
Study 28146613 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole Once-Monthly 400 mg (AOM 400)
Number of subjects: 266
Study 28146613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study 26420671 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing medical education workshop (See One)
Number of subjects: 40
Study 26420671 — intervention group
Group type: EXPERIMENTAL
Intervention: Apprenticeship model with live supervision (Do One)
Number of subjects: 40
Study 26420671 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordering MI from psychiatry consultation‐liaison service (Order One)
Number of subjects: 40
Study 26420671 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 40
Study 23837810 — intervention group
Group type: EXPERIMENTAL
Intervention: Popular Opinion Leader (POL) intervention
Number of subjects: 880
Study 23837810 — intervention group
Group type: COMPARATOR
Intervention: Non-POL providers (Control)
Number of subjects: 880
Study 21724580 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) supplementation (800 IU/d)
Number of subjects: 92
Study 21724580 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2 g/d)
Number of subjects: 92
Study 21724580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 19410250 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal therapy
Number of subjects: 101
Study 19410250 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-periodontitis)
Number of subjects: 101
Study 17492350 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Number of subjects: 44
Study 17492350 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated Hib vaccine
Number of subjects: 44
Study 17492350 — intervention group
Group type: COMPARATOR
Intervention: Control group (T)
Number of subjects: 44
Study 17492350 — intervention group
Group type: EXPERIMENTAL
Intervention: HM group
Number of subjects: 44
Study 15145966 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin 50 mg, 75 mg, or 100 mg daily intravenous infusions preceded by a loading dose that was twice the daily dose.
Number of subjects: 225
Study 15145966 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 225
Study 11467870 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute Calogen
Number of subjects: 71
Study 11467870 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 71
Study 11467870 — intervention group
Group type: COMPARATOR
Intervention: 2% sodium diatrizoate
Number of subjects: 71
Study 8770428 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular neuroleptic medication
Number of subjects: 71
Study 8770428 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal from medication
Number of subjects: 71
Study 8770428 — intervention group
Group type: EXPERIMENTAL
Intervention: Life events
Number of subjects: 71
Study 1581815 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin prophylaxis
Number of subjects: 140
Study 1581815 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime prophylaxis
Number of subjects: 140
Study 1581815 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic cover
Number of subjects: 140
Study 3882270 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg sublingually
Number of subjects: 12
Study 30833310 — intervention group
Group type: EXPERIMENTAL
Intervention: Camera-based mirror visual feedback (camMVF) intervention group
Number of subjects: 90
Study 30833310 — intervention group
Group type: EXPERIMENTAL
Intervention: Shielded mirror visual feedback intervention group
Number of subjects: 90
Study 30833310 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy group
Number of subjects: 90
Study 30114680 — intervention group
Group type: EXPERIMENTAL
Intervention: Good School Toolkit intervention
Number of subjects: 3820
Study 27687456 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleth Variability Index (PVI)
Number of subjects: 40
Study 27687456 — intervention group
Group type: COMPARATOR
Intervention: Esophageal Doppler
Number of subjects: 40
Study 25592946 — intervention group
Group type: EXPERIMENTAL
Intervention: Huxin Formula
Number of subjects: 270
Study 25592946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 25592946 — intervention group
Group type: COMPARATOR
Intervention: Control group (Placebo)
Number of subjects: 270
Study 22545895 — intervention group
Group type: EXPERIMENTAL
Intervention: PEVI + anticoagulation
Number of subjects: 183
Study 22545895 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation alone
Number of subjects: 183
Study 19851098 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal bridling of feeding tubes
Number of subjects: 80
Study 17933158 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (bolus and infusion throughout surgery)
Number of subjects: 88
Study 17933158 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 88
Study 15615752 — intervention group
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy (PPV) with internal limiting membrane (ILM) peeling
Number of subjects: 40
Study 15615752 — intervention group
Group type: COMPARATOR
Intervention: Further macular laser
Number of subjects: 40
Study 12149533 — intervention group
Group type: EXPERIMENTAL
Intervention: AS+NRT (Nicotine patches daily and inhalator as needed plus advice and support)
Number of subjects: 245
Study 12149533 — intervention group
Group type: COMPARATOR
Intervention: AS (Advice and support only)
Number of subjects: 245
Study 10431581 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined androgen blockade alone (Group-A)
Number of subjects: 44
Study 10431581 — intervention group
Group type: COMPARATOR
Intervention: Combined androgen blockade with UFT (Group-B)
Number of subjects: 44
Study 8775649 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual intercourse 12 hours prior to maximal treadmill exercise
Number of subjects: 11
Study 8775649 — intervention group
Group type: COMPARATOR
Intervention: No sexual intercourse prior to maximal treadmill exercise
Number of subjects: 11
Study 1934240 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (10 mg/kg body weight twice daily) for 1 day (3 doses)
Number of subjects: 64
Study 1934240 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (10 mg/kg body weight twice daily) for 2 days
Number of subjects: 64
Study 1934240 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (10 mg/kg body weight twice daily) for 4 days
Number of subjects: 64
Study 1934240 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (10 mg/kg body weight twice daily) for 7 days
Number of subjects: 64
Study 7106043 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle ergometer load for 10 minutes (group I)
Number of subjects: 35
Study 7106043 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 20-percent lipofundin followed by ergometer load (group II)
Number of subjects: 35
Study 7106043 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of lipofundin without subsequent physical stress (group III)
Number of subjects: 35
Study 30770763 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pain competence and depression prevention training (Intervention Group)
Number of subjects: 583
Study 30770763 — intervention group
Group type: COMPARATOR
Intervention: Pain competence training (Control Group)
Number of subjects: 583
Study 28181128 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise program
Number of subjects: 160
Study 28181128 — intervention group
Group type: COMPARATOR
Intervention: Relaxation control group
Number of subjects: 160
Study 28181128 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 160
Study 27085783 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle change aimed at achieving 7% weight loss
Number of subjects: 3070
Study 27085783 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850mg twice daily
Number of subjects: 3070
Study 27085783 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 3070
Study 24879138 — intervention group
Group type: EXPERIMENTAL
Intervention: S-O clip-assisted ESD
Number of subjects: 70
Study 24879138 — intervention group
Group type: COMPARATOR
Intervention: Conventional ESD
Number of subjects: 70
Study 21592974 — intervention group
Group type: EXPERIMENTAL
Intervention: UACR in the fourth quartile (≥ 6.1 mg/g)
Number of subjects: 1272
Study 21592974 — intervention group
Group type: EXPERIMENTAL
Intervention: UACR in the third quartile (3.8-6.1 mg/g)
Number of subjects: 1272
Study 21592974 — intervention group
Group type: COMPARATOR
Intervention: UACR in the lowest quartile (<2.8 mg/g)
Number of subjects: 1272
Study 19165497 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic fundoplication (RALF)
Number of subjects: 40
Study 19165497 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic fundoplication (CLF)
Number of subjects: 40
Study 17122382 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate 5 mg twice daily
Number of subjects: 27
Study 17122382 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate 10 mg twice daily
Number of subjects: 27
Study 17122382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 15259618 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 16
Study 15259618 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with sleep apnea syndrome
Number of subjects: 16
Study 11244190 — intervention group
Group type: EXPERIMENTAL
Intervention: HDF three times per week (Group 3)
Number of subjects: 112
Study 11244190 — intervention group
Group type: EXPERIMENTAL
Intervention: HDF (duration > 12 months)
Number of subjects: 112
Study 11244190 — intervention group
Group type: COMPARATOR
Intervention: HDF
Number of subjects: 112
Study 9558692 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological therapy for rate control
Number of subjects: 0
Study 9558692 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological therapy for rhythm control
Number of subjects: 0
Study 9558692 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug selection algorithm for rate control
Number of subjects: 0
Study 7992236 — intervention group
Group type: EXPERIMENTAL
Intervention: Running velocity at anaerobic threshold (VAT)
Number of subjects: 16
Study 7992236 — intervention group
Group type: EXPERIMENTAL
Intervention: Running velocity at 95% of blood lactate concentration of 4 mM (V4mM)
Number of subjects: 16
Study 3044507 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan
Number of subjects: 0
Study 31880009 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (TeenPower) for 6 months in addition to a school-based intervention
Number of subjects: 0
Study 31655496 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone administration
Number of subjects: 2
Study 31655496 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone administration
Number of subjects: 2
Study 31655496 — intervention group
Group type: COMPARATOR
Intervention: GC-C-IRMS method
Number of subjects: 2
Study 28222999 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise, interactive education intervention (prenatally, postnatally, and 1 month after birth)
Number of subjects: 188
Study 28222999 — intervention group
Group type: COMPARATOR
Intervention: Control group received a leaflet containing general information on immunization
Number of subjects: 188
Study 26674499 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 400 IU vitamin D supplementation
Number of subjects: 3012
Study 23095610 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic blood transfusion
Number of subjects: 475
Study 23095610 — intervention group
Group type: COMPARATOR
Intervention: Autologous blood transfusion
Number of subjects: 475
Study 20105697 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia or daytime fatigue with MetS
Number of subjects: 2753
Study 20105697 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufficient sleep with MetS
Number of subjects: 2753
Study 20105697 — intervention group
Group type: COMPARATOR
Intervention: MetS only
Number of subjects: 2753
Study 20105697 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufficient sleep and MetS
Number of subjects: 2753
Study 17510001 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-item asthma-specific questionnaire with pharmacist interaction (group 1)
Number of subjects: 60
Study 17510001 — intervention group
Group type: COMPARATOR
Intervention: Standard care only (group 2)
Number of subjects: 60
Study 17510001 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 16243339 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (600 mg) plus CLA (450 mg)
Number of subjects: 48
Study 16243339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12374334 — intervention group
Group type: EXPERIMENTAL
Intervention: 330-340-nm excitation
Number of subjects: 146
Study 12374334 — intervention group
Group type: EXPERIMENTAL
Intervention: 350-380-nm excitation
Number of subjects: 146
Study 12374334 — intervention group
Group type: EXPERIMENTAL
Intervention: 400-450-nm excitation
Number of subjects: 146
Study 10333943 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting 32,33 split proinsulin
Number of subjects: 1071
Study 10333943 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose concentration
Number of subjects: 1071
Study 10333943 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting insulin
Number of subjects: 1071
Study 10333943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact proinsulin
Number of subjects: 1071
Study 10333943 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of family history, fasting glucose, and total proinsulin
Number of subjects: 1071
Study 8704653 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term head and neck cancer survivors
Number of subjects: 204
Study 8704653 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 204
Study 2190549 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg pyridostigmine bromide every 8 h
Number of subjects: 10
Study 2190549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 379704 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfecillin (250 mg and 500 mg p.o.)
Number of subjects: 26
Study 379704 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfecillin
Number of subjects: 26
Study 379704 — intervention group
Group type: COMPARATOR
Intervention: Indanyl ester of carbenicillin (control)
Number of subjects: 26
Study 31389531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cases of aggression perpetrated by unknown assailants
Number of subjects: 787
Study 29045800 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading group (n = 81)
Number of subjects: 158